Cabozantinib from Dr. Reddy's

Leading manufacturer and supplier of high-quality, affordable Active Pharmaceutical Ingredients (API) to leading generic formulations manufacturers worldwide, enabling them to accelerate access to affordable medicines for patients worldwide.

The availability of high-quality, affordable active pharmaceutical ingredients (APIs) is critical to delivering good health to all. Dr. Reddy’s API business supplies high-quality, affordable APIs to leading generic formulations manufacturers worldwide, enabling them to accelerate access to affordable medicines...

Read full company description
Address: 8-2-337, Road No. 3, Banjara Hills, Hyderabad, ., Telangana, 500034
India
India Local time:

Diverse portfolio of 180+APIs

1754+ DMF across global markets

1100+ patents filed, and more than 70 own patents granted

Our clients:

All API Buyers

Our services:

API
FDF
Pre-Formulations
CDMO

Response time:

Producer

Produced in:

India

MOQ: -

  • GMP

  • CoA

  • WC

  • FDA

  • MSDS

  • BSE/TSE

  • USDMF

Contact supplier

Replies quickly

Dr. Reddy's Cabozantinib API Producer - 849217-68-1

Description:
Dr. Reddy's offers high-quality Cabozantinib API, certified for compliance with international standards. Manufactured in India. Diverse portfolio of 180+APIs. 1754+ DMF across global markets. 1100+ patents filed, and more than 70 own patents granted.

Product Details

Certifications
GMP, CoA, WC, FDA, MSDS, BSE/TSE, USDMF compliant
Minimum Order Quantity
Produced in
India (Asia)
DrugBank ID
DB08875
CAS Number
849217-68-1
Unique Ingredient Identifier
1C39JW444G
Raw Material Category
Protein kinase inhibitors

Ordering Process

1. Inquiry Submission: Click "Send Inquiry" to connect directly with producer.

2. Requirement Specification: Outline your needs for tailored offers.

3. Quotation: Receive the best quote and terms exclusively through Pharmaoffer.

Quality Assurance

Dr. Reddy's has successfully passed audits conducted by Eurofins, with reports available that underscore the company's commitment to quality and transparency.

Dr. Reddy's has successfully passed audits conducted by Rephine, with reports available that underscore the company's commitment to quality and transparency.

Additional Products

We offer 169 other Active Pharmaceutical Ingredients and excipients, showcasing our production and distribution capabilities.

Contact Us

Are you looking for Cabozantinib API? Contact Dr. Reddy's by using the send inquiry button. We will respond quickly with pricing and terms exclusively through Pharmaoffer.

Please, provide enough information regarding your inquiry. Let us know whether you require Ph.Eur (EP), USP, BP, JP grade, whether you are looking for hydrochloride (HCl), base, or other specific product specifications. Additionally, please inform us if the API is intended for your own production, resale, or research purposes. Contact us to receive a quote, download certificates, and purchase the Cabozantinib API

Dr. Reddy's


Leading manufacturer and supplier of high-quality, affordable Active Pharmaceutical Ingredients (API) to leading generic formulations manufacturers worldwide, enabling them to accelerate access to affordable medicines for patients worldwide.

The availability of high-quality, affordable active pharmaceutical ingredients (APIs) is critical to delivering good health to all. Dr. Reddy’s API business supplies high-quality, affordable APIs to leading generic formulations manufacturers worldwide, enabling them to accelerate access to affordable medicines for patients worldwide. We are the preferred API partner to pharma companies across the US, Europe, Latin America, Japan, China, Korea, and emerging markets.

Our business thrives on the deep technical strengths established over the last 30+ years in developing and manufacturing complex APIs such as steroids, peptides, complex long-chain molecules, and highly potent APIs (HPAIs /oncology drugs). This expertise is complemented by our intellectual property and regulatory affairs prowess, which helps us consistently meet and exceed regulatory standards.